"..We have reaffirmed our 2023 guidance on the back of a strong first quarter," continued Mr. Logan. "Our end markets remain supportive of our growth expectations and our teams are focused on executing upon our expectations for the remainder of the year." Mirion is reaffirming its guidance for the fiscal year and 12-month period ending December 31 : Reported revenue growth of 6% – 9% Organic revenue growth of 4% – 7% Adjusted EBITDA of $172M- $182M Adjusted EPS of 28c – $ 34c; Adjusted free cash flow of $58M – $78M inorganic revenue growth is expected to be approximately 1.5%, including benefits from the SIS acquisition, offset by the Biodex rehab divestiture, which closed early in the second quarter. Foreign exchange rates are expected to result in a positive 0.5% impact to revenue growth. The guidance for organic revenue growth excludes
Published first on TheFly
